<DOC>
	<DOCNO>NCT00721552</DOCNO>
	<brief_summary>The investigator ass whether DPP-inhibitor sitagliptin ameliorate glucocorticoid-induced impairment glucose metabolism beta-cell dysfunction thus could use prophylaxis glucocorticoid-induced diabetes . Therefore investigator administer male metabolic syndrome 30 mg prednisolone daily two week give simultaneously sitagliptin 100 mg daily . Subjects undergo baseline two week treatment several test assess change glucose metabolism .</brief_summary>
	<brief_title>Sitagliptin Prophylaxis Glucocorticoid-Induced Impairment Glucose Metabolism Males With Metabolic Syndrome</brief_title>
	<detailed_description>The investigator conduct randomize , placebo-controlled , double-blind , 2x2 factorial-designed intervention trial . The pharmacological intervention prednisolone/prednisolone-placebo 14 day sitagliptin/sitagliptin-placebo 28 day . Subjects fulfil IDF criteria26 metabolic syndrome ( age 35-65 ; n=60 ) randomize one four group : I ) prednisolone 30 mg sitagliptin 100 mg daily ; II ) prednisolone 30 mg sitagliptin-placebo daily ; III ) prednisolone-placebo sitagliptin 100 mg daily ; IV ) prednisolone-placebo sitagliptin-placebo daily . Before day 14 treatment subject undergo standardize mixed-meal test order ass glucose disposal beta-cell function ( model analysis ) . During meal test , plasma concentration ( total active ) GLP-1 , GIP , glucagon additional biomarkers assess . A combined hyperglycemic-euglycemic clamp perform baseline day 13 treatment assess insulin sensitivity insulin secretion . During euglycemic clamp adipose tissue muscle biopsy obtain , fast hyperinsulinemic condition . At baseline day 28 treatment , 7-point OGTT perform assess time restoration glycemic control . Body composition , body fat distribution liver fat content , measure respectively bio-impedance analysis magnetic resonance imaging/spectroscopy ( MRI/MRS ) , assess baseline 28 day treatment . Blood pressure assess baseline two week treatment . Microvascular function assess capillary videomicroscopy baseline two week treatment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>Caucasian male Modified IDF criterion metabolic syndrome : Waist circumference ≥ 94 cm And least 2 follow criterion : TG ≥ 1.7 mmol/L HDL cholesterol &lt; 1.03 mmol/L Blood pressure &gt; 130/85 mmHg ( average three measurement ) treatment previously diagnose hypertension Fasting plasma glucose level ( FPG ) ≥ 5.6 mmol/L ( diabetes ) An allergic anaphylactic reaction prednisolone treatment past Clinically relevant history presence medical disorder , mention Summary Product Characteristics ( SPC ) contraindication use prednisolone Glucocorticosteroid use last three month prior first dose Participation investigational drug trial within 90 day prior first dose Donation blood ( &gt; 100 mL ) within 90 day prior first dose History current abuse drug alcohol ( &gt; 14 U/week ) Use grapefruit product study period Recent change weight and/or physical activity Serious mental impairment language problem i.e . prevent understand study protocol/aim Diabetes mellitus ( define FPG ≥ 7.0 mmol/l and/or 2hPG ≥ 11.1 mmol/l ) Serious pulmonary , cardiovascular , hepatic ( ALT , AST 3x ULN ) renal disease ( serum creatinine &gt; 135 micromol/L ) History cardiovascular disease , myocardial infarction , cerebrovascular accident . Major psychiatric disorder , depression All diseases induce change hypothalamicpituitaryadrenal ( HPA ) axis Malignant disease All relevant medical disorder potentially interfere trial . All medication interfere study drug interfere study endpoints/hypotheses</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>beta-cell function</keyword>
	<keyword>glucocorticoid-induced diabetes</keyword>
	<keyword>glucocorticoid</keyword>
	<keyword>DPP-4 inhibitor</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>steroid diabetes</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>insulin sensitivity</keyword>
</DOC>